Process
Portfolio
Insights
People
Places
Press
Login
Process
Portfolio
Insights
People
Places
Press
Login
LOGIN
PRESS
October 10, 2024
RIVERMARK MEDICAL CLOSES $30 MILLION SERIES C FINANCING TO ADVANCE DEVELOPMENT OF FLOSTENT™ SYSTEM FOR BENIGN PROSTATIC HYPERPLASIA
September 17, 2024
Invenra Welcomes Three Industry Leaders to Its Board of Directors
August 23, 2024
Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment
August 7, 2024
Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors
July 10, 2024
EnsoData expands sleep apnea screening and diagnosis capabilities with new acquisition
April 15, 2024
Elucent Medical Secures Series C Funding to Advance Oncologic Surgery Innovation
April 10, 2024
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery
April 10, 2024
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
April 3, 2024
Earlitec announces $21.5M Series B to commercialize Earlipoint Evaluation and advance product development
April 1, 2024
ViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucoma
February 26, 2024
Latest EnsoData FDA 510(k) Clearance Enables AI-Powered Sleep Diagnosis Using Pulse Oximetry Devices
February 20, 2024
Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments
February 20, 2024
Elephas to Collaborate with Mayo Clinic to Advance Development of Oncology Imaging Diagnostics Platform
January 29, 2024
Elephas Announces $55 Million in Series C Funding
November 10, 2023
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
November 3, 2023
ViaLase Completes Enrollment for the Pivotal VIA-002 Trial of the ViaLase® Laser to Treat Primary Open Angle Glaucoma
October 11, 2023
FDA approves histotripsy for liver treatment in humans
October 9, 2023
FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System
August 24, 2023
Visana Health Secures $10.1M in Seed Funding to Scale Its Virtual-First Women’s Healthcare Model
August 24, 2023
Delphinus Raises $12M for Its 3D Whole Breast Ultrasound Tomography System to Invest in Further Expansion
August 17, 2023
Visana Health Secures $10.1M in Seed Funding to Scale Its Virtual-First Women’s Healthcare Model
May 16, 2023
Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas
March 31, 2023
HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy
December 13, 2022
UM spin-out HistoSonics raises $85 million to continue path toward commercialization
November 21, 2022
Delphinus Medical Technologies to Demonstrate SoftVue™ Whole Breast Ultrasound System at RSNA Annual Meeting
November 21, 2022
Could this new ultrasound change the way cancer is treated? – BBC News
November 9, 2022
New Data Published in the Journal of Infectious Diseases Demonstrate FluGen’s M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains
October 18, 2022
Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022
September 29, 2022
Delphinus Raises 30 million in Series D Funding to Transform Dense Breast Screening
September 23, 2022
Detroit’s Karmanos First in World to Receive the SoftVue Breast Imaging System
September 22, 2022
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
September 20, 2022
Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter
September 19, 2022
HistoSonics Announces Published Results of Phase I Liver Tumor Trial
September 7, 2022
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
June 22, 2022
FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
June 8, 2022
Leading Healthcare Artificial Intelligence Company Raises $20m Series A Extension
June 2, 2022
Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting
June 1, 2022
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
May 23, 2022
HistoSonics Announces Agreement with GE Healthcare
April 28, 2022
Inspire Medical Systems, Inc. Announces Investments in EnsoData and Ognomy
April 11, 2022
Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting
January 25, 2022
Venture Investors Health Fund Announces Jenni Le Has Joined the Firm as an Associate
December 15, 2021
Venture Investors Health Fund announces that Shelly Lanning has joined the firm as a Venture Partner.
December 9, 2021
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
November 10, 2021
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers
November 3, 2021
Koura, an Orbia Company, Acquires Battery Technology Company Silatronix to Meet Growing Global Demand for Energy Storage
October 20, 2021
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia
October 18, 2021
HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy
October 18, 2021
Delphinus Receives FDA Approval for its SoftVue 3D Whole Breast Ultrasound Tomography System
August 16, 2021
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
August 10, 2021
New Virtual Reality (VR) Training from Health Scholars and the American Academy of Pediatrics Aims to Help EMS Save Children’s Lives
August 3, 2021
FluGen flu vaccine research ramps up as work on COVID-19 candidate slows
August 2, 2021
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
July 15, 2021
Iterion Therapeutics Hires Jean Chang as Chief Operating Officer
July 12, 2021
HistoSonics Announces Milestone As American Medical Association Issues Unique Category III CPT® Code For Histotripsy Of Liver
July 12, 2021
Flywheel and HealthMyne Partner to Provide End-to-End Radiomic Data Management and Analysis
July 1, 2021
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
June 24, 2021
BioForward Recognizes Scientific and Business Success with Annual Wisconsin Biohealth Awards
June 7, 2021
HistoSonics Announces First Patient Treated in European Clinical Trial
June 4, 2021
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2021
Ultrasound Technology Developed at U-M now in Clinical Trials for Liver Cancer
May 25, 2021
FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85
May 17, 2021
Drone software company SkySpecs makes acquisitions as focus on wind power increases
May 7, 2021
Published Research Validates HealthMyne’s Radiomic Technology as a Robust Predictor of Tumor Response and Biomarker Identification
April 14, 2021
Ann Arbor cancer drug startup aims to start human testing, gets $1.2 million seed round
April 14, 2021
Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
February 17, 2021
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
February 17, 2021
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
February 3, 2021
HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors
January 21, 2021
This New Device Is Revolutionizing Breast Surgery at Fox Chase Cancer Center
January 21, 2021
Tampa General Hospital Among the First in Nation to Participate in Study of New Investigative Device Designed to Destroy Tumors without Surgery
January 7, 2021
RefleXion and HealthMyne Collaborate to Use Patient’s Tumor Data to Guide Cancer Therapy
December 14, 2020
Jim Adox: Look for more health care investment in 2021
December 1, 2020
EnsoData Founders Named to Forbes 30 Under 30
October 26, 2020
HealthMyne Cited Among Top 10 Startups in Madison for Fourth Consecutive Year
October 7, 2020
HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study
October 1, 2020
FluGen CEO talks Covid-19 vaccine development in Bytes with the Beat event
September 18, 2020
QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems
August 24, 2020
Ann Arbor-based NeuMoDx expands footprint, increases COVID-19 testing production
August 13, 2020
QIAGEN to move forward with full acquisition of NeuMoDx, adding versatile integrated molecular testing platforms to portfolio and gaining access to U.S. and other markets
August 6, 2020
NeuMoDx Molecular Announces CE Marking for Quantitative BKV Assay
June 17, 2020
NeuMoDx Molecular Announces CE Marking for HIV Viral Load Assay
June 12, 2020
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
June 10, 2020
NeuMoDx Molecular Introduces High Volume Nucleic Acid Extraction Capability
June 10, 2020
HistoSonics Lands $40M Series C-1 To Perfect Precision Therapy
June 10, 2020
EnsoData Raises $9M To Diagnose Health Conditions With AI
April 14, 2020
FluGen and UW-Madison doctors work to create COVID-19 vaccine
April 2, 2020
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
March 31, 2020
NeuMoDx Announces US FDA Emergency Use Authorization (EUA) for SARS-CoV2 Test
March 12, 2020
NEUMODX PREPARING TO LAUNCH CORONAVIRUS TEST
February 28, 2020
QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2
February 19, 2020
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study
February 17, 2020
Leading Lung Cancer Expert Joins HealthMyne Clinical Advisory Board
February 6, 2020
FRED LEE, MD, PART OF TEAM THAT DEVELOPS GPS DEVICE TO BETTER LOCATE BREAST CANCER TUMORS DURING SURGERY
January 21, 2020
UW-Madison professors create revolutionary GPS device to help surgeons find breast cancer tumors during removal
January 17, 2020
Health Scholars, the Virtual Reality Healthcare Training Platform, Raises $17M in Series B funding.
January 13, 2020
HistoSonics Wins Top Honors in The Observer’s List of Top Healthcare Start-ups Heading into the JP Morgan Healthcare Conference
January 8, 2020
Breast surgery device by company with UW founders now in use
January 6, 2020
HistoSonics Robotic Sonic Beam Therapy Platform Wins 2019 Frost & Sullivan Innovation Award
January 6, 2020
Rose Higgins Named CEO of HealthMyne
January 6, 2020
UW-Madison inventors aim to replace old-style breast-surgery marker
December 23, 2019
Drone-inspection company Skyspecs raises $17 million funding round
December 11, 2019
NeuMoDx Molecular, Sentinel Diagnostics Partner for MDx Development
December 9, 2019
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
November 1, 2019
myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients
October 31, 2019
Invenra Announces Expansion of Collaboration with Exelixis
October 30, 2019
SSM Health doctors first in world to use new breast cancer removal technology
October 30, 2019
Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 28, 2019
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund
October 13, 2019
SSM Health St. Mary’s Hospital – Madison First Hospital to Use (Elucent’s) Innovative Breast Cancer Marker System
October 10, 2019
Fighting the flu: Shot clinics, local researchers work for better outcomes
October 10, 2019
Venture Investors closes on $75 million VC fund, opens Milwaukee office
October 3, 2019
Venture Investors Announces Final Closing on Venture Investors Health Fund 6 Limited Partnership
September 24, 2019
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
September 16, 2019
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
August 14, 2019
Silatronix® Awarded Navy ONR Contract for Organosilicon Electrolytes for Safe, High Energy, High-Nickel Magnesium Cobalt Li-ion Batteries.
August 14, 2019
CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study
July 30, 2019
Rock Mackie to be Recognized by ASTRO and IOMP
July 24, 2019
NEUMODX™ LAUNCHES CE-IVD ASSAYS FOR CMV & EBV
June 24, 2019
NeuMoDx™ Launches CE-IVD Assays For HBV & HCV
May 21, 2019
Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
May 15, 2019
CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
May 13, 2019
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
April 16, 2019
HistoSonics raises $54M for medical robotics platform
April 12, 2019
QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version
April 11, 2019
Elucent Medical Receives FDA Clearance for Innovation for Breast Tumor Removal Procedures
April 8, 2019
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
March 21, 2019
FirstHealth of the Carolinas Selects HealthMyne
March 19, 2019
FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
February 25, 2019
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131
February 12, 2019
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
January 31, 2019
Invenra and WARF Initiate a Collaboration to Discover and Develop Novel Therapeutics to Fight Neuroblastoma in Children
January 29, 2019
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
January 7, 2019
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
December 11, 2018
Cellectar Granted Japanese Patent for CLR 131
December 4, 2018
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
December 3, 2018
From poet and ski bum to disease fighter: Roland Green
November 29, 2018
Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas
November 27, 2018
Meet the Founder of Tai Diagnostics, One of Milwaukee’s Most-Funded Startups
November 19, 2018
Madison pharmaceutical developer FluGen raises $5.6 million
November 13, 2018
InsideWis: Reach of angel, venture capital extends beyond portfolio companies
November 12, 2018
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies
November 9, 2018
Eximis Working on a New Surgical Platform
October 24, 2018
Invenra Secures $7M in Series B Growth Round to Accelerate Bispecific Antibody Development
October 22, 2018
FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains
October 5, 2018
FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week
October 2, 2018
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
September 24, 2018
SkySpecs – Leader in Automated Drone Inspections & Analytics Software – Reaches 33,000 Autonomous Wind Turbine Blade Inspections
September 24, 2018
Children are the latest test subjects of FluGen’s universal flu vaccine
September 17, 2018
Experimental nasal influenza vaccine tested in kids, teens
September 17, 2018
QIAGEN and NeuMoDx announce strategic partnership to offer next-generation systems for fully integrated molecular diagnostic testing
September 17, 2018
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
September 10, 2018
HealthMyne Enters Joint Development Agreement with Mayo Clinic
August 30, 2018
Receipt of Commercial Orders for (Silatronix) OS3 Electrolyte Material
August 23, 2018
Cancer Screening Module in Latest Version of HealthMyne QIDS Platform Automates Patient Tracking to Improve Care
August 20, 2018
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
August 13, 2018
Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma
August 1, 2018
HealthMyne Raises $15 Million in Series B Round to Expand Commercialization Efforts
August 1, 2018
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
July 31, 2018
New scanning device gives doctors 3D image of breast to detect cancer
July 25, 2018
NEUMODX MOLECULAR ANNOUNCES FDA 510(K) CLEARANCE FOR ITS N288 MOLECULAR SYSTEM AND GBS ASSAY
July 18, 2018
Ørsted Partners with SkySpecs to Conduct Automated Robotic Inspection on World’s Largest Offshore Wind Turbine Blades
July 17, 2018
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study
July 9, 2018
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 3, 2018
Fresh Off Launch of First Test, TAI Diagnostics Adds Funding
June 28, 2018
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
June 27, 2018
Silk Road Medical CEO Erica Rogers mixes science and art to fight strokes
June 8, 2018
Midwestern Tech Transfer Offices and Investors Forging Closer Ties, says MGCS Panelists
June 7, 2018
Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131
June 6, 2018
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
May 29, 2018
FluGen tests its influenza vaccine against the wrong strain of flu — on purpose
May 16, 2018
FluGen Begins Enrollment of Clinical Trial of Novel Investigational Influenza Vaccine Against Multi-Season Mismatched Strains
May 7, 2018
NanoBio raises $10 million funding round, changes name
May 3, 2018
SkySpecs – Leader in Automated Drone Inspections – Unveils New Horizon Software at the AWEA Windpower Exhibition in Chicago
May 2, 2018
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
May 2, 2018
FluGen May Seek Funding from $12M Gates-Backed Flu Vaccine Challenge
March 15, 2018
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
February 28, 2018
Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury
February 15, 2018
Here’s why it’s so hard to make a better flu vaccine
February 12, 2018
Akebia Therapeutics Provides Update on Vadadustat Development Program
February 9, 2018
Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
February 7, 2018
Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma
February 6, 2018
Madison-based company will test ‘revolutionary’ universal flu vaccine this spring
January 29, 2018
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
January 29, 2018
FluGen to launch new test of its universal flu vaccine in May
January 26, 2018
Novel ultrasound device may better detect cancers among women with dense breast tissue
January 19, 2018
Madison-based company has developed a new vaccine for the flu
January 17, 2018
Wind Industry Embraces Robots to Boost Safety, Cut Costs
January 10, 2018
Get ready, some medical experts are predicting the worst flu season in history
January 9, 2018
SkySpecs proves value of automated drone inspections with at-scale operations; lands $8M investment to accelerate global growth and bring actionable insights to renewable energy industry
January 9, 2018
TAI Diagnostics Closes $10M Financing and Establishes Collaboration Agreement with United Therapeutics
January 4, 2018
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
December 15, 2017
Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers
December 7, 2017
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
November 14, 2017
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer
November 14, 2017
Delphinus to Host Dense Breast Subject Experts at RSNA 2017
November 7, 2017
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
October 30, 2017
New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation
October 26, 2017
Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors
October 24, 2017
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
October 23, 2017
EnteroMedics Announces Name Change to ReShape Lifesciences Inc. (NASDAQ: RSLS)
October 23, 2017
FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched Strains
October 23, 2017
New HealthMyne QIDS 3.0 Platform Addresses Incidental Findings Workflow
October 23, 2017
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
October 10, 2017
Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
October 10, 2017
Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as CEO and to the Board and the Transition of Joseph H. Gardner, Ph.D., to President and Founder
October 10, 2017
Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
October 3, 2017
EnteroMedics Announces Acquisition Of ReShape Medical
September 27, 2017
Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
September 26, 2017
Akebia’s vadadustat successful in mid-stage study in Japan, Phase 3 planned; shares ahead 5% premarket
September 25, 2017
Research leads to better flu vaccine
September 25, 2017
Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 21, 2017
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
September 19, 2017
HistoSonics Expands Leadership Team As It Accelerates Growth
September 19, 2017
FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair
September 9, 2017
Delphinus Announces First Patient Enrolled in Clinical Project Comparing SoftVue™ and Mammography in Dense Breast Tissue
September 7, 2017
Silatronix awarded $1 million Navy ONR contract
September 6, 2017
FluGen Announces C. Boyd Clarke Has Been Named Executive Chairman
August 22, 2017
Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window
August 11, 2017
This Detroit Drone Startup is Helping Lift the City’s Economy to New Heights
August 9, 2017
Madison’s FluGen plans new human trials of universal flu vaccine
August 8, 2017
Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
August 8, 2017
Aerpio Pharmaceuticals Commences Trading on the OTCQB® Market
August 2, 2017
Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 Plus Keytruda® for Metastatic, Treatment-Resistant Prostate Cancer
August 1, 2017
Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
July 20, 2017
New White Paper from HealthMyne Reveals Breakthroughs in Quantitative Imaging for Oncology
June 29, 2017
Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
June 21, 2017
Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017
June 19, 2017
NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine
June 14, 2017
Delphinus Appoints Global R&D Leader Bruno Dacquay as New Vice President of Engineering
June 8, 2017
HistoSonics Technology’s Exciting Preclinical Results to be Presented at the World Conference on Interventional Oncology (WCIO) 2017
May 25, 2017
Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
May 15, 2017
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
May 2, 2017
Silatronix Featured in The Science Coalition Sparking Economic Growth, Volume 3
April 26, 2017
Akebia, Otsuka pen $865M expansion to anemia pill pact
April 25, 2017
Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers
April 20, 2017
DePuy Synthes Acquires Tissue Regeneration System’s 3D Printing Technologies to Treat Bone Defects
April 18, 2017
Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
April 12, 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
April 12, 2017
FluGen Raises $2M More, Provides Update on Phase 1 Trial
April 11, 2017
Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
March 30, 2017
After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
March 29, 2017
Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
March 22, 2017
Madison Vaccines Incorporated Expands Clinical Trial of MVI-118 for Prostate Cancer to University of Washington
March 20, 2017
Wisconsin venture capital group resurrected
March 16, 2017
Aerpio Pharmaceuticals successfully completes reverse merger and closes private placement of $40 Million
March 13, 2017
HistoSonics gains new leaders, turns focus to oncology
March 9, 2017
HealthMyne Introduces New Website and Brand Identity
March 8, 2017
Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement
March 3, 2017
Otsuka Pharmaceutical to Acquire Neurovance, Inc., a VIESF IV Portfolio Company
March 3, 2017
Self-flying drones collect data on wind turbine blades
February 28, 2017
US Drones fly for Siemens: SkySpecs partnership to advance drone technology for wind inspections
February 27, 2017
Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months
February 22, 2017
Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma
February 21, 2017
After Navigating Ups and Downs, Cellectar CEO Caruso Looks to Future
February 20, 2017
Madison-based Silatronix develops groundbreaking technology for better batteries
February 13, 2017
Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation
January 31, 2017
Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform
January 26, 2017
Printed human body parts could soon be available for transplant
January 24, 2017
Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors
January 23, 2017
Elucent, With $7.2M in Tow, Advances Breast Cancer Treatment Device
December 20, 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
December 20, 2016
Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs
December 14, 2016
Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development — Executive Board Chairman Jeff Bailey Becomes CEO
December 14, 2016
Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types
December 12, 2016
Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035
December 12, 2016
Akebia Prevails in Additional European Patent Dispute
December 6, 2016
Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology
December 1, 2016
Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies
November 30, 2016
Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option
November 28, 2016
Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production
November 21, 2016
HealthMyne Helps Attendees of RSNA Make a Difference
November 21, 2016
U.S. Senator Tammy Baldwin Tours Advanced Wisconsin Battery Manufacturer Silatronix
November 17, 2016
Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors
November 15, 2016
HealthMyne to Introduce Quantitative Imaging Decision Support (QIDS)™ Platform at RSNA
November 15, 2016
Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial
November 11, 2016
Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results
November 11, 2016
Akebia Announces Third Quarter 2016 Financial Results — Multiple Publications Highlight Vadadustat’s Potential to Treat Renal Anemia and the Need for New Therapies for Chronic Kidney Disease — Company Expands Leadership Team with Additional Expertise in HIF Biology and Clinical Development
November 11, 2016
Dow AgroSciences and Chromatin Announce Exclusive Commercial License Agreement for Unique Sorghum Genetics
November 11, 2016
Madison Vaccines Says Promising Early Data on the Combination of Its Lead Prostate Cancer Vaccine with a PD-1 Inhibitor Will Be Presented at Major Medical Meeting Nov. 11th
November 11, 2016
ReShape Medical, Inc. Unveils US Commercial Data Demonstrating Increased Weight Loss with ReShape® Dual Balloon
November 11, 2016
Cellectar drug data possible in 2017
November 11, 2016
Silatronix making lithium-ion batteries safer and more reliable
November 11, 2016
Cellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies
November 11, 2016
Madison Vaccines Incorporated Says Its Investigational New Prostate Cancer Treatment is Available for the First Time in New Jersey Through a Clinical Trial at Rutgers Cancer Institute of New Jersey
October 6, 2016
Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma
October 4, 2016
PES caught up with Danny Ellis, CEO and co-Founder of Skyspecs, to hear about the latest drone inspection technology
October 4, 2016
Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603
September 29, 2016
TEDxDetroit speaker Christine Gibbons to innovators: Keep focus on patient care
September 29, 2016
Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma
September 27, 2016
HealthMyne raises $6.9 million
September 27, 2016
Aerpio Therapeutics Initiates Phase 1a Study of AKB-4924 in Development to Treat Inflammatory Bowel Disease (IBD)
September 19, 2016
Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
September 19, 2016
Strategic Consortium Announced to Commercialize Virent’s BioForming Technology for Low Carbon Fuels and Bio-Paraxylene
September 14, 2016
Tumor Ablation Expert Dr. Fred Lee, Jr. Joins HistoSonics as Board Member, Senior Medical Advisor
September 13, 2016
HealthMyne adds new Chief Medical & Informatics Officer (CMIO) to its leadership team
September 13, 2016
HealthMyne Names New CEO and Board Member with Deep Expertise and Experience in Healthcare Technology
September 12, 2016
Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant
September 7, 2016
SkySpecs To Demonstrate Drone Inspection Of Wind Turbines
September 7, 2016
Takeda Initiates Phase 3 Clinical Trial of Dengue Vaccine Candidate Acquired from Inviragen
September 6, 2016
Tesoro to Acquire Virent in Support of Commercializing Renewable Fuels and Chemicals
August 24, 2016
WIN panel urges keeping strong patent protections
August 22, 2016
Dingell Announces Small Business Voucher Award for SkySpecs of Ann Arbor
August 22, 2016
Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
August 9, 2016
Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
August 8, 2016
ReShape Medical Announces the Appointment of Michael J. Mangano as President and Chief Executive Officer
August 3, 2016
Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study
July 27, 2016
FluGen Initiates a Phase 1 Clinical Trial of the RedeeFlu™ Universal Influenza Vaccine in Healthy Subjects
July 27, 2016
Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials
July 21, 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
June 30, 2016
Fred Lee, The UW Radiologist With Startup Vision
June 23, 2016
FluGen co-founder Kawaoka to receive Japan Academy award, presented by Emperor and Empress
June 23, 2016
Chromatin, Inc. Acquires Kirkland Seed, a Sorghum Production and Supply Company
June 23, 2016
Silatronix has Raised New Equity Capital and Formed Several New International Partnerships
June 23, 2016
Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer
June 15, 2016
Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel
June 13, 2016
Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial
June 13, 2016
UW-Madison’s ‘Rock’ Mackie rocks business plan contest
May 24, 2016
HealthMyne’s Mark Gehring to receive ‘Seize the Day’ award
May 23, 2016
Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
May 23, 2016
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO
May 17, 2016
Madison company invents compound to make lithium-ion batteries safer
May 17, 2016
Delphinus Relocates Headquarters, Triples Size of Facility
May 16, 2016
Sales near for Delphinus ultrasonic breast cancer detector
May 16, 2016
Lithium-ion battery technology propels Madison energy storage company
May 16, 2016
‘Milwaukee Quick Pitch’ is a big hit
April 26, 2016
From farm products to T-shirts using Virent’s technology
April 25, 2016
Madison-made electrolyte going big at global battery manufacturer
April 21, 2016
VIRENT BIOFORMPX® PARAXYLENE USED TO PRODUCE WORLD’S FIRST 100% PLANT BASED POLYESTER SHIRTS
April 18, 2016
Michigan rises in the ranks of venture capital investment
April 15, 2016
ETHICON ANNOUNCES COMPLETION OF ACQUISITION OF NEUWAVE MEDICAL, INC.
April 5, 2016
Chromatin Announces Relief Program for Sorghum Growers Hit by the Kansas-Oklahoma Fire
March 30, 2016
Zaad and Chromatin Agree to Produce and Distribute Sorghum Seed in Africa
March 28, 2016
Vaccines could help treat cancer
March 18, 2016
Growers Who Planted Chromatin’s Sorghum Partners® Brand Seed Have Winning Yields in the 2015 National Sorghum Producers Yield Contest
March 9, 2016
Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat
March 9, 2016
NeuWave Medical to be acquired by a J&J company
March 8, 2016
Ethicon Announces Agreement To Acquire NeuWave Medical, Inc.
March 4, 2016
Swinging for the fences powers Delphinus Medical Technologies
March 2, 2016
(SkySpecs founders) make Forbes list
February 24, 2016
Meet Danny Ellis, the CEO and co-founder of SkySpecs.
February 16, 2016
Chromatin Acquires Sorghum Seed Distributor Majestic Semillas
February 11, 2016
Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study
February 9, 2016
Juventas Therapeutics announces Phase 2 gene therapy trial for artery disease treatment
February 2, 2016
Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer
February 1, 2016
Virent Announces Strategic Collaboration with Tesoro to Advance the Commercialization of Virent’s BioForming Technology for Low Carbon Fuels and Chemicals
January 29, 2016
HealthMyne receives “Most Promising Company” Award at the 2016 PMWC
January 19, 2016
HealthMyne Receives FDA Clearance for its Imaging Analytics Software
January 7, 2016
NEUROVANCE ANNOUNCES SERIES OF THREE CLINICAL TRIALS TO SUPPORT ADVANCED DEVELOPMENT OF CENTANAFADINE (CTN) IN ADULT ADHD
January 7, 2016
Neurovance Appoints Jeff Bailey to Chair Its Board of Directors
January 7, 2016
Virent Bio-Jet Provides More Than 50% Reduction in Particulate Matter Emissions
January 7, 2016
Cellectar Biosciences Announces Positive Data From Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma
December 16, 2015
Cellectar Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration
December 14, 2015
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
December 3, 2015
NanoBio’s Chlamydia Vaccine Improves Clearance of Bacteria, Prevents Pelvic Inflammatory Disease in Mice
November 23, 2015
TAI Diagnostics Closes $8.2M Series A Financing
November 23, 2015
Will The San Francisco Bay Area Dominate Digital Healthcare?
November 17, 2015
HealthMyne Adds Epic EHR Data to Imaging Analytics Platform
November 10, 2015
Mackie honored as his latest startup shifts toward high gear
November 9, 2015
SkySpecs closes on $3M funding round, lands first customers
November 3, 2015
HealthMyne Adds Healthcare IT Industry Expert to Board
October 27, 2015
A Hot New Weight Loss Procedure Helped This Woman Drop 70 Lbs. – Without Surgery
October 6, 2015
HealthMyne, Inc. and Moffitt Cancer Center Sign Imaging Analytics Technology Agreement
October 6, 2015
Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program
October 1, 2015
Cellectar Biosciences Awarded $2.3M National Cancer Institute Fast-Track SBIR Grant to Advance Phospholipid Drug Conjugate (PDC) Delivery Platform
September 23, 2015
Nanobio’s Genital Herpes Vaccine Demonstrates Efficacy in Guinea Pigs as Both a Prophylactic and a Therapeutic Vaccine
September 18, 2015
Madison Vaccines Says Clinical Trial Begins for Its 2nd Prostate Cancer Vaccine, MVI-118, Intended to Delay Disease Progression in Men with Metastatic Disease
September 11, 2015
Delphinus Raises Over $39 Million in Capital
September 11, 2015
Akebia Therapeutics Announces Additions to its Management Team
September 9, 2015
Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease
September 8, 2015
Madison’s Silatronix to lead study to develop a better lithium-ion battery
August 28, 2015
Alfalight Receives 2015 Wisconsin Innovation Award
August 25, 2015
HealthMyne Announces FDA Clearance of Imaging Informatics Platform
August 25, 2015
FLUGEN CLOSES $12 MILLION SERIES A FINANCING
August 25, 2015
Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics
August 20, 2015
MADISON VACCINES ANNOUNCES PATIENT DOSING UNDERWAY IN CLINICAL TRIAL PAIRING ITS LEAD PROSTATE CANCER VACCINE, MVI-816, WITH PD1 INHIBITOR PEMBROLIZUMAB
August 13, 2015
NEUWAVE MEDICAL, INC., RECEIVES FDA CLEARANCE FOR ABLATION CONFIRMATION SOFTWARE
August 13, 2015
HEALTHMYNE, INC., AND UNIVERSITY OF WISCONSIN MOVE FORWARD WITH IMAGING INFORMATICS IMPLEMENTATION
July 15, 2015
AERPIO THERAPEUTICS ANNOUNCES POSITIVE RESULTS OF A PHASE 2A STUDY OF AKB-9778 IN DIABETIC MACULAR EDEMA: THE TIME-2 TRIAL
July 10, 2015
ALFALIGHT COMPLETES DELIVERY OF 850 WEAPON-MOUNTED LASERS
July 3, 2015
A CHAT WITH CELECTAR’S NEW CEO
June 29, 2015
INTEGRATED PEST PROGRAM HELPS SORGHUM GROWERS
June 16, 2015
JUVENTAS THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION AND PHASE 2B PROTOCOL ALLOWANCE FOR NOVEL HEART FAILURE GENE THERAPY
June 16, 2015
CELLECTAR APPOINTS INDUSTRY VETERAN JIM CARUSO PRESIDENT AND CHIEF EXECUTIVE OFFICER
June 3, 2015
VIRENT BIOFORMPX PARAXYLENE USED FOR WORLD’S FIRST PET PLASTIC BOTTLE MADE ENTIRELY FROM PLANT-BASED MATERIAL
June 1, 2015
ALLIQUA BIOMEDICAL, INC. ANNOUNCES CLOSING OF CELLERATION, INC. ACQUISITION
May 29, 2015
EUTHYMICS REPORTS TOP-LINE RESULTS FROM TRIADE TRIAL OF AMITIFADINE FOR MAJOR DEPRESSIVE DISORDER
May 29, 2015
AKEBIA ANNOUNCES PRESENTATION OF PHASE 2B DATA FOR AKB-6548 IN NON-DIALYSIS PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE AT THE 52ND ERA-EDTA CONGRESS
May 28, 2015
NEUWAVE MEDICAL INC. CLOSES $25 MILLION IN NEW FINANCING
May 28, 2015
NEUWAVE MEDICAL INC. CLOSES $25 MILLION IN NEW FINANCING
May 26, 2015
JUVENTAS THERAPEUTICS PRESENTS NEW 12-MONTH DATA DEMONSTRATING SINGLE ADMINISTRATION OF JVS-100 IMPROVES CARDIAC AND CLINICAL STATUS IN PATIENTS WITH SEVERE ISCHEMIC HEART FAILURE ONE YEAR AFTER TREATMENT
May 18, 2015
TISSUE REGENERATION SYSTEMS $4.09 MILLION FUNDRAISING. WILLIAM J. FITZSIMMONS SUBMITTED MAY 18 SEC FORM
May 12, 2015
JUVENTAS THERAPEUTICS ADDS $13.5 MILLION IN NEW FINANCING AND EXPANDS BOARD OF DIRECTORS
May 11, 2015
HEALTHMYNE, INC. ADDS DEL COUFAL AS VP OF MARKETING AND BUSINESS DEVELOPMENT
April 22, 2015
AKEBIA THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES
April 21, 2015
OXFORD FINANCE AND SILICON BANK CLOSE $12 MILLION SENIOR CREDIT FACILITY WITH RESHAPE MEDICAL
April 16, 2015
CHROMATIN: SORGHUM PARTNERS ANNOUNCES SUGARCANE APHID INTEGRATED PEST MANAGEMENT PROGRAM
April 15, 2015
CELLECTAR BIOSCIENCES INITIATES PROOF-OF-CONCEPT TRIAL OF I-131-CLR1404 IN MULTIPLE MYELOMA
April 13, 2015
ALFALIGHT: HIGH-POWER LASER SPINOFF PROVES VERSATILITY IS STRENGTH
April 7, 2015
FDA SAYS RESHAPE MEDICAL CAN SKIP ADVISORY PANEL FOR OBESITY BALLOON DEVICE
March 30, 2015
CELLECTAR BIOSCIENCES: READY, AIM, FIRE! CANCER-TARGETING MECHANISM UNDERLIES PROMISING UW-MADISON SPINOFF
March 26, 2015
MIST THERAPY DEMONSTRATES BETTER HEALING AND REDUCED RECIDIVISM IN SPLIT THICKNESS DONOR SITE RANDOMIZED CONTROLLED TRIAL
March 18, 2015
CHROMATIN SORGHUM HYBRIDS PRODUCE FIVEFOLD YIELD INCREASE IN EAST AFRICA
March 16, 2015
AKEBIA ANNOUNCES PRESENTATION OF RESULTS FROM ITS PHASE 2B STUDY OF AKB-6548 IN NON-DIALYSIS PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE AT THE INTERNATIONAL SOCIETY OF NEPHROLOGY’S WORLD CONGRESS OF NEPHROLOGY
March 16, 2015
AKEBIA TRIAL SHOWS ANEMIA DRUG SPURS “CONTROLLED” RESPONSE
March 12, 2015
MADISON VACCINES EXPANDS INVESTIGATIONAL PROSTATE CANCER VACCINES
March 10, 2015
MADISON VACCINES EXPANDS SERIES A TO ADVANCE PROSTATE CANCER DRUGS
March 10, 2015
HEALTHMYNE RAISES $4.5M IN SERIES A ROUND OF VENTURE CAPITAL FINANCING
March 10, 2015
AKEBIA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 TRIAL OF AKB-6548 IN DIALYSIS PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE
March 4, 2015
AERPIO THERAPEUTICS ANNOUNCES PUBLICATION OF POSITIVE RESULTS OF PHASE 1B/2A CLINICAL TRIAL OF NOVEL TIE2 ACTIVATOR, AKB-9778, FOR THE TREATMENT OF PATIENTS WITH DIABETIC MACULAR EDEMA (DME) – TIME-1 STUDY
February 26, 2015
CHROMATIN EXPANDS ITS EXECUTIVE TEAM
February 25, 2015
CHROMATIN, INC. ANNOUNCES PRODUCTION OF FARNESENE IN SORGHUM
February 19, 2015
CHROMATIN: SORGHUM PARTNERS BRINGS MARKET LEADING HYBRIDS TO NORTH CAROLINA
February 18, 2015
NEUWAVE MEDICAL: EXERGEN GLOBAL’S TEMPERATURE SENSOR ENSURES SAFETY, EFFICIENCY FOR ABLATION SYSTEMS
February 11, 2015
CHROMATIN EXPANDING ITS PRESENCE IN THE REGION
February 2, 2015
ALLIQUA BIOMEDICAL, INC. TO ACQUIRE CELLERATION, INC.
January 30, 2015
VENTURE INVESTORS’ PORTFOLIO COMPANY, TISSUE REGENERATION SYSTEMS (TRS), COLLABORATION WITH JOHNSON & JOHNSON VIDEO
January 28, 2015
VENTURE INVESTORS: MICHIGAN VENTURE CAPITAL INVESTMENT VALUE UP NEARLY 100% FROM 2013
January 27, 2015
CELLERATION, INC. ANNOUNCES STATISTICALLY SIGNIFICANT BETTER HEALING WITH MIST THERAPY IN THE IN-BALANCE VLU RANDOMIZED CONTROL TRIAL
January 22, 2015
ALFALIGHT RECEIVES $1.9M RAYTHEON CONTRACT TO DELIVER LASER SUBSYSTEMS FOR AEROSPACE APPLICATION
January 22, 2015
COKE’S PLANT BOTTLE – COCA COLA INVESTS FURTHER IN SCALING VIRENT’S PARAXYLENE PRODUCTION
January 22, 2015
PEER-REVIEWED GLIOMA SURGERY STUDY WITH CELLECTAR BIOSCIENCES FLUORESCENCE CANCER-TARGETING AGENTS CHOSEN FOR THE COVER OF NEUROSURGERY
January 15, 2015
UPTO INTROS PLUGIN FOR CHROME, BRINGS FEATURES TO GOOGLE CALENDAR
January 14, 2015
TISSUE REGENERATION SYSTEMS ADDS BUSINESS DEVELOPMENT EXECUTIVE
January 8, 2015
SILATRONIX: UW GRANT PROGRAM SEEDS PROMISING IDEAS, LIKE SAFER BATTERIES
January 5, 2015
AKEBIA COMPLETES ENROLLMENT IN THE TWO PLANNED COHORTS OF ITS PHASE 2 STUDY OF AKB-6548 IN PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE UNDERGOING DIALYSIS
December 17, 2014
HISTOSONICS: UNIVERSITIES PUSH HARDER INTO REALM OF STARTUPS
December 17, 2014
WISCONSIN STILL MISSING AN INGREDIENT IN THE START-UP STEW
December 15, 2014
AKEBIA THERAPEUTICS, INC. ADDED TO NASDAQ BIOTECHNOLOGY INDEX
December 11, 2014
NEUROVANCE ANNOUNCES TOP-LINE STUDY RESULTS SUGGEST LOWER ABUSE POTENTIAL FOR CENTANAFADINE COMPARED TO STIMULANTS USED FOR ADULT ADHD
December 11, 2014
VIRENT ANNOUNCES WORLD’S FIRST DEMONSTRATION OF FULL RANGE BIO-AROMATICS PRODUCTION
December 4, 2014
AERPIO THERAPEUTICS COMPLETES ENROLLMENT OF PHASE 2 STUDY OF TIE2 ACTIVATOR AKB-9778 FOR THE TREATMENT OF PATIENTS WITH DIABETIC MACULAR EDEMA
December 4, 2014
CELLECTAR BIOSCIENCES GRANTED ORPHAN DESIGNATION FOR I-131-CLR1404 FOR THE TREATMENT OF MULTIPLE MYELOMA
December 4, 2014
CHROMATIN: SORGHUM PARTNERS SORGHUM HYBRIDS DEMONSTRATE TOLERANCE AGAINST SUGARCANE APHIDS
November 27, 2014
RESHAPE MEDICAL: A BALLOON MAY AID WEIGHT LOSS
November 25, 2014
CELLECTAR BIOSCIENCES NAMES CAMERON SZAKACS, PH.D. VICE PRESIDENT OF CLINICAL DEVELOPMENT
November 24, 2014
VIRENT: SHELL EXPECTS TO BE PRODUCING ADVANCED BIOFUELS AT SCALE, IN US, BY END OF DECADE
November 24, 2014
RESHAPE MEDICAL: A BALLOON FOR OBESITY – AN OPTION BETWEEN MEDICATION AND SURGERY?
November 19, 2014
CHROMATIN: TECHAG DEMONSTRATES EXCEPTIONAL PERFORMANCE OF SORGHUM PARTNERS HYBRID SORGHUM PRODUCTS IN MEXICO
November 18, 2014
JUVENTAS THERAPEUTICS PRESENTS PHASE II DATA AT AHA SCIENTIFIC SESSIONS THAT SHOWS JVS-100 IS SAFE, POTENTIALLY EFFECTIVE IN PATIENTS WITH CRITICAL LIMB ISCHEMIA
November 13, 2014
CHROMATIN INC. APPOINTS TROY RANDOLPH AS CHIEF FINANCIAL OFFICER
November 4, 2014
RESHAPE MEDICAL UNVEILS US PIVOTAL TRIAL RESULTS FOR NON-SURGICAL WEIGHT LOSS PROCEDURE FEATURED IN TOP 10 PAPER AT OBESITY WEEK 2014
November 4, 2014
VIRENT: THE NEW ALCHEMY? COMPANY MAKES JET FUEL AND PLASTIC SODA BOTTLES OUT OF FARM WASTES
October 30, 2014
VIRENT AND THE PLANTPET TECHNOLOGY COLLABORATIVE (PTC) SIGN EXPRESSION OF INTEREST TO ACCESS COMMERCIAL QUANTITIES OF VIRENT’S BIOFORMPX PARAXYLENE
October 28, 2014
CHROMATIN, INC. RECEIVES GOVERNOR’S EXPORT AWARD
October 28, 2014
JUVENTAS THERAPEUTICS STRENGTHENS MANAGEMENT TEAM WITH NEW SENIOR VICE PRESIDENT OF FINANCE AND OPERATIONS
October 27, 2014
AKEBIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2B STUDY OF AKB-6548 IN NON-DIALYSIS PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE
October 22, 2014
VENTURE INVESTORS FOUNDER ROGER GANSER ELECTED TO STATE’S INVESTOR HALL OF FAME
October 15, 2014
NEUWAVE MEDICAL CORRALS $4.8M FOR TUMOR-ZAPPING TECH
October 14, 2014
DELTANOID’S DP001 (2MD) PHARMACEUTICAL DEMONSTRATED SAFE AND EFFECTIVE IN KIDNEY FAILURE PATIENTS ON DIALYSIS
October 8, 2014
NANOBIO TO PRESENT DATA DEMONSTRATING THE POTENTIAL FOR ITS INTRANASAL VACCINE TO PROTECT AGAINST GENITAL HERPES INFECTION
October 7, 2014
HISTOSONICS: BLAZING NEW TRAILS IN MEDICINE
October 1, 2014
RESHAPE MEDICAL – 2014 FIERCE 15
September 30, 2014
VIRENT HIRES EDGAR STEENWINKEL TO LEAD TECHNOLOGY DEVELOPMENT EFFORTS
September 27, 2014
THALCHEMY: A “SMART” MOVE FOR ELECTRONICS
September 25, 2014
AKEBIA ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 STUDY OF AKB-6548 IN PATIENTS WITH ANEMIA RELATED TO CHRONIC KIDNEY DISEASE UNDERGOING DIALYSIS
September 23, 2014
ALFALIGHT RECEIVES $3.7M CONTRACT TO DELIVER TECHNOLOGY FOR THAAD MISSILE DEFENSE SYSTEM
September 16, 2014
TISSUE REGENERATION SYSTEMS: STARTUP USES 3D PRINTING TECH TO CREATE ALTERNATIVE TO BONE GRAFTS
September 15, 2014
AKEBIA THERAPEUTICS APPOINTS RONALD C. RENAUD JR. TO ITS BOARD OF DIRECTORS
September 8, 2014
VIRENT TO EXPAND DEMO PLANT CAPABILITIES TO SCALE PLANT-BASED PARAXYLENE
September 6, 2014
CELLECTAR & MVI: TWO MADISON BIOTECHS TO ADVANCE WITH DRUG TRIALS; A MEDICAL DEVICE COMPANY RECEIVES FUNDS
September 4, 2014
CELLECTAR BIOSCIENCES ANNOUNCES ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO EVALUATE I-131-CLR1404 IN CLINICAL TRIALS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
September 2, 2014
AERPIO THERAPEUTICS ANNOUNCES PUBLICATION OF PRECLINICAL DATA ON AKB-9778 FOR COMMON EYE DISEASES
August 28, 2014
RESHAPE MEDICAL ANNOUNCES NEW DATA SHOWING CLINICALLY SIGNIFICANT WEIGHT LOSS WITH THE RESHAPE PROCEDURE IN EU COMMERCIAL USE
August 28, 2014
RESHAPE TARGETS U.S. APPROVAL AS EU STUDY SHOWS MAJOR WEIGHT LOSS
August 27, 2014
MVI VACCINE TO BE USED IN CLINICAL TRIAL OF A NEW COMBINATION APPROACH TO IMMUNOTHERAPY FUNDED BY THE PROSTATE CANCER FOUNDATION AND THE MOVEMBER FOUNDATION
August 22, 2014
TISSUE REGENERATION SYSTEMS NABS $4.6M TO IMPROVE FACIAL SURGERIES
August 21, 2014
TISSUE REGENERATION SYSTEMS TO COLLABORATE WITH J&J, DEPUY SYNTHES
August 20, 2014
CELLERATION ANNOUNCES NEXT GENERATION ULTRAMIST SYSTEM RECEIVES FDA CLEARANCE
August 20, 2014
CELLECTAR BIOSCIENCES ANNOUNCES CLOSING OF PUBLIC OFFERING AND PARTIAL EXERCISE OF UNDERWRITER’S OVER-ALLOTMENT OPTION
August 18, 2014
MADISON VACCINES RIDES IMMUNOTHERAPY WAVE WITH EARLY-STAGE PROSTATE DRUG
August 12, 2014
JUVENTAS THERAPEUTICS COMPLETES ENROLLMENT OF PHASE I/II RETRO-HF TRIAL AND DEMONSTRATES SAFETY FOR RETROGRADE INFUSION OF JVS-100 IN PATIENTS WITH HEART FAILURE
August 12, 2014
VIRENT RECEIVES EPA REGISTRATION FOR ITS BIOFORM GASOLINE
August 7, 2014
NEUROVANCE COMPLETES ENROLLMENT IN HUMAN ABUSE LIABILITY STUDY FOR CENTANAFADINE (FORMERLY CALLED EB-1020) FOR ADULT ADHD
August 6, 2014
AKEBIA THERAPEUTICS ANNOUNCES EXPANSION OF MANAGEMENT TEAM
August 5, 2014
NEUROVANCE APPOINTS BRIGITTE ROBERTSON, MD, VICE PRESIDENT, CLINICAL DEVELOPMENT
July 28, 2014
CHROMATIN: PACIFIC ETHANOL AWARDED $3 MILLION GRANT TO SUPPORT SORGHUM FEEDSTOCK PROGRAM
July 23, 2014
CHROMATIN, INC. ACQUIRES SORGHUM PRODUCTION AND SUPPLY COMPANY, PRODUCTION SEEDS PLUS, INC.
July 23, 2014
JUVENTAS THERAPEUTICS STRENGTHENS LEADERSHIP TEAM BY ADDING TWO INDUSTRY VETERANS
July 17, 2014
AKEBIA THERAPEUTICS APPOINTS MICHAEL CLAYMAN, M.D. AND MAXINE GOWEN, PH.D. TO ITS BOARD OF DIRECTORS
July 10, 2014
NETSOCKET ENTERS STRATEGIC PARTNERSHIP WITH SOLUTION PROVIDER CHUANHOW TECH
July 9, 2014
CHROMATIN, INC. SECURES $12.5 MILLION CREDIT FACILITY WITH THE PRIVATEBANK
July 9, 2014
NETSOCKET LAUNCHES NETSOCKET VIRTUAL PARTNER PROGRAM FOR TECHNOLOGY PARTNERS
July 1, 2014
RESHAPE MEDICAL SUBMITS PMA APPLICATION TO FDA FOR NON-SURGICAL WEIGHT LOSS DEVICE
June 30, 2014
AKEBIA THERAPEUTICS ADDED TO RUSSELL 3000, RUSSELL 2000 AND RUSSELL GLOBAL INDEXES
June 26, 2014
TRS: JOHNSON & JOHNSON PLANS TO DEVELOP A LINE OF 3-D PRINTED RECONSTRUCTIVE IMPLANTS
June 25, 2014
CHROMATIN AND ACI LAUNCH NEW SORGHUM PRODUCTS IN ALGERIA
June 25, 2014
THALCHEMY RAISES SEED FUNDS TO DEVELOP ALWAYS-ON SENSOR TECHNOLOGY
June 23, 2014
MADISON VACCINES INCORPORATED ANNOUNCES EXPANSION OF A PHASE 2 CLINICAL TRIAL FOR MVI-816, ITS LEAD DNA VACCINE FOR PROSTATE CANCER
June 19, 2014
TRS: JOHNSON & JOHNSON INNOVATION CATALYZES NEW AND EXCITING SCIENCE AND TECHNOLOGY IN PARMACEUTICAL, MEDICAL DEVICE, DIAGNOSTIC AND CONSUMER HEALTH SPACES
June 14, 2014
CHROMATIN: THE MOLECULAR BIOLOGIST WHO WOULD FEED THE WORLD SORGHUM
June 10, 2014
ALFALIGHT RECEIVES $49M IDIQ CONTRACT FOR DELIVERY OF OCULAR INTERRUPTION LASER SYSTEM TO U.S. MARINE CORP
June 10, 2014
NEUMODX AND JEFF WILLIAMS CAPITALIZE ON LESSONS LEARNED AT HANDYLAB
June 3, 2014
NETSOCKET ROLLS OUT NEW SUITE OF VIRTUALIZED APPLICATIONS ENABLING MSPS TO GROW REVENUE AND DELIVER PROFITABLE NEW MANAGED SERVICES
May 29, 2014
ALFALIGHT RECEIVES $49M IDIQ CONTRACT FOR DELIVERY OF OCULAR INTERRUPTION LASER SYSTEM TO US MARINE CORPS
May 29, 2014
CELLECTAR BIOSCIENCES APPOINTS CHAD J. KOLEAN CHIEF FINANCIAL OFFICER
May 28, 2014
LOCAL BIOTECH’S HEART FAILURE TREATMENT SHOWS PROMISE – JUVENTAS TO LAUNCH PHASE 3 STUDY NEXT YEAR
May 27, 2014
AKEBIA AIMS BIG WITH POTENTIAL DRUG FOR ANEMIA DUE TO CHRONIC KIDNEY DISEASE
May 20, 2014
HISTOSONICS NEARS CLOSE OF $14.2M FUNDING FOR NON-INVASIVE ABLATION
May 14, 2014
MADISON VACCINES ANNOUNCES THE APPOINTMENT OF MICHAEL RICHMAN TO ITS BOARD OF DIRECTORS
May 12, 2014
NEUWAVE MEDICAL, INC. NAMES DANIEL J. SULLIVAN AS PRESIDENT AND CEO
May 8, 2014
NEUROVANCE’S EB-1020 SR FOR ADULT ADHD SHOWS STIULANT-LIKE EFFICACY IN PHASE 2A TRIAL
May 5, 2014
CELLECTAR BIOSCIENCES ANNOUNCES RECEIPT OF ORPHAN DESIGNATION OF I-124-CLR1404 AS DIAGNOSTIC FOR THE MANAGEMENT OF GLIOMA FROM U.S. FOOD AND DRUG ADMINISTRATION
May 5, 2014
AERPIO THERAPEUTICS PRESENTS FULL RESULTS FROM PHASE 1B/2A STUDY OF AKB-9778 FOR THE TREATMENT OF DIABETIC MACULAR EDEMA AT ARVO ANNUAL MEETING
April 23, 2014
AERPIO THERAPEUTICS CLOSES $22M FINANCING
April 14, 2014
AKEBIA SOARS WITH ANALYSTS’ HIGH HOPES
April 3, 2014
NEUROVANCE CLOSES $6.3M FINANCING TO SUPPORT FURTHER DEVELOPMENT OF EB-1020 SR IN ADULT ADHD
April 2, 2014
CELLECTAR BIOSCIENCES NAMES NEW PRESIDENT, CEO
April 1, 2014
RESHAPE DUO BALLOON OFFERS BARIATRIC SURGERY ALTERNATIVE
March 27, 2014
UPTO LAUNCHES A CALENDAR APP FOR THE FOMO GENERATION
March 27, 2014
UPTO INTRODUCES THE CALENDAR OF THE FUTURE
March 26, 2014
AKEBIA THERAPEUTICS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES
March 26, 2014
MERCK LICENSES NANOBIO TECHNOLOGY
March 26, 2014
NEUMODX ANNOUNCES COMPLETION OF SERIES B FINANCING
March 13, 2014
CELLERATION REACHES KEY MILESTONE OF 1 MILLION MIST THERAPY TREATMENTS
March 7, 2014
ANEMIA BIOTECH AKEBIA THERAPEUTICS SETS TERMS FOR $76 MILLION IPO
February 27, 2014
CHROMATIN, INC. ANNOUNCES FIVE NEW SORGHUM PRODUCTS
February 25, 2014
CHROMATIN, INC. ANNOUNCES PRODUCTION OF FARNESENE IN SORGHUM
February 18, 2014
AKEBIA THERAPEUTICS FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING
February 13, 2014
AERPIO THERAPEUTICS INITIATES PHASE 2 STUDY OF TIE2 ACTIVATOR AKB-9778 FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
February 11, 2014
NETSOCKET INTRODUCES COMPLETELY VIRTUALIZED NETWORK SOLUTION OPTIMIZED FOR THE NETWORK EDGE
February 4, 2014
JUVENTAS THERAPEUTICS INITIATES PHASE II RETRO-HF CLINICAL TRIAL ENROLLMENT FOR PATIENTS WITH HEART FAILURE
February 2, 2014
SILATRONIX: NEW INVESTMENTS HAVE A MADISON BATTERY COMPANY ALL CHARGED UP
January 27, 2014
CHROMATIN, INC. ANNOUNCES WINNERS IN NATIONAL SORGHUM PRODUCERS ANNUAL COMPETITION
January 13, 2014
AKEBIA THERAPEUTICS STRENGTHENS ITS LEADERSHIP TEAM WITH KEY ADDITIONS
January 13, 2014
MADISON VACCINES CLOSES $8 MILLION SERIES A FINANCING
January 9, 2014
CHROMATIN, INC. CLOSES NEW FINANCING ROUND, ADDS PRIVATE EQUITY INVESTORS
January 9, 2014
NEUROVANCE SAYS INTERIM DATA FROM PHASE 2A PILOT STUDY OF EB-1020 SR SHOWS STIMULANT-LIKE EFFICACY, BUT WITH LOWER RISK OF ABUSE, FOR ADULT ADHD
January 8, 2014
ALFALIGHT RECEIVES $1.7M CONTRACT FOR DELIVERY OF MARITIME DEFENSE LASER MODULES
December 24, 2013
HISTOSONICS: LOCAL COMPANY’S MEDICAL DEVICE GETS TRIAL TREATMENT USE AT U-M
December 19, 2013
VC IN 2014: VENTURE INVESTORS’ JOHN NEIS ON IMPROVING RETURNS IN LIFE SCIENCES
December 9, 2013
JUVENTAS THERAPEUTICS INITIATES FIRST CLINICAL TRIAL FOR RETROGRADE INFUSION OF A GENE THERAPY TO PATIENTS WITH HEART FAILURE
December 6, 2013
ICIS INNOVATION AWARD WINNERS, RENMATIX AND VIRENT, ANNOUNCE COLLABORATION ON BIO-BASED PACKAGING
November 26, 2013
JIM ADOX AND VENTURE INVESTORS CHARGE FULL STEAM AHEAD
November 13, 2013
ANN ARBOR’S HISTOSONICS NAMED INNOVATOR OF THE YEAR
November 8, 2013
MVCA CELEBRATES YEAR’S TOP DEALS, NAMES NEW BOARD CHAIR
November 7, 2013
RESHAPE MEDICAL SUCCESSFULLY MEETS ENDPOINTS IN WEIGHT LOSS DEVICE PIVOTAL TRIAL
November 6, 2013
AERPIO THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1B/2A TRIAL IN DIABETIC MACULAR EDEMA AND $9 MILLION SERIES A EXTENSION
October 29, 2013
NANOBIO AWARDED UP TO $10 MILLION IN NIH FUNDING TO DEVELOP A PANDEMIC INFLUENZA VACCINE
October 28, 2013
JUVENTAS THERAPEUTICS COMPLETES ENROLLMENT OF PHASE II STOP-HF STUDY OF JVS-100 IN PATIENTS WITH SYMPTOMATIC HEART FAILURE
October 16, 2013
AKEBIA APPOINTS JASON A. AMELLO AS SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER
October 2, 2013
NETSOCKET ANNOUNCES VIRTUALIZED NETWORKING SOLUTION OPTIMIZED FOR THE DISTRIBUTED ENTERPRISE
September 24, 2013
NEUROVANCE ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR EB-1020 SR AND INITIATES PHASE 2A STUDY IN ADULT ADHD
September 14, 2013
NEW VENTURE INVESTORS FUND RAISES $80 MILLION
September 14, 2013
VIRENT DEVELOPING ENVIRONMENTALLY FRIENDLY BOTTLES FOR COKE
August 28, 2013
AKEBIA APPOINTS RENAL INDUSTRY VETERAN JOHN P. BUTLER AS PRESIDENT AND CEO
August 26, 2013
TISSUE REGENERATION SYSTEMS RECEIVES 510K APPROVAL
August 8, 2013
HISTOSONICS STARTS CLINICAL TRIAL FOR NON-INVASIVE PROSTATE TREATMENT
August 6, 2013
AERPIO THERAPEUTICS REPORTS PUBLICATION OF DATA ON TIE2 ACTIVATOR, AKB-9778
July 24, 2013
AKEBIA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2B TRIAL OF ORAL ANEMIA CANDIDATE
July 23, 2013
DETROIT’S UPTO PIVOTS, COMPLETES A $2 MILLION SERIES A ROUND
July 22, 2013
AKEBIA: OHIO 2Q VENTURE CAPITAL INVESTMENT NEARLY DOUBLES
July 19, 2013
AKEBIA LEADS OHIO FUNDING IN SECOND QUARTER
July 18, 2013
NETSOCKET VIRTUALIZES END-TO-END SDN SOLUTION, OFFERS FREE DOWNLOAD OF PLATFORM
July 11, 2013
NETSOCKET SHIFTS GEARS FROM MANAGING UNIFIED COMMUNICATIONS TO ENABLING SOFTWARE DEFINED NETWORKS
July 11, 2013
UPTO 2.0 RE-INVENTS THE CALENDAR, THIS TIME TARGETING GOOGLE, OUTLOOK, AND APPLE
July 9, 2013
NETSOCKET UNVEILS VIRTUALIZED SDN SOLUTION
July 8, 2013
VIRENT EARNS AWARD FOR NEXT GENERATION BIOFUEL CONVERSION
July 8, 2013
PLANO-BASED NETSOCKET REVEALS WHAT IT DID WITH $9.2 MILLION IN VENTURE CAPITAL IT RAISED THIS YEAR
July 8, 2013
NETSOCKET UNVEILS INDUSTRY’S FIRST END-TO-END COMPLETELY VIRTUALIZED SDN SOLUTION
July 8, 2013
NETSOCKET TARGETS CISCO WITH SDN PITCH
July 2, 2013
NETSOCKET’S CLOUD EXPERIENCE MANAGER NOW WORKS WITH MICROSOFT LYNC SERVER
June 30, 2013
WHAT’S ON TAP? UPTO CHECKS OFF MILESTONES OF GROWTH FOR ITS SOCIAL CALENDAR APP
June 24, 2013
NETSOCKET CLOUD EXPERIENCE MANAGER QUALIFIED AS INTEROPERABLE WITH LYNC NETWORK DIAGNOSTICS API
June 20, 2013
NEXTT: TIRED OF BEING SOCIAL? MAYBE IT’S TIME TO JOIN AN “ANTI-SOCIAL” NETWORK
June 19, 2013
NEXTT RAISES $700,000 IN SEED FUNDING TO LAUNCH PRIVATE SOCIAL NETWORK FOR FRIENDS TO DO MORE TOGETHER IN THE REAL WORLD
June 19, 2013
NEXTT RAISES $700,000 IN SEED FUNDING TO LAUNCH PRIVATE SOCIAL NETWORK FOR FRIENDS TO DO MORE TOGETHER IN THE REAL WORLD
June 13, 2013
CHROMATIN INC. TO PARTNER WITH THE SORGHUM CHECKOFF TO ACCELERATE GRAIN SORGHUM DEVELOPMENT
June 5, 2013
NETSOCKET NAMED AMONG TOP FINALISTS FOR THE 2013 MICROSOFT START-UP PARTNER OF THE YEAR – EMERGING MARKETS AWARD
June 4, 2013
AKEBIA CLOSES $41 MILLION SERIES C
May 16, 2013
NOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE
May 8, 2013
TAKEDA TO ACQUIRE INVIRAGEN
May 7, 2013
NETSOCKET NAMED “COOL VENDOR” BY LEADING ANALYST FIRM GARTNER
May 1, 2013
VIRENT’S NEW PILOT PLANT PRODUCES RENEWABLE JET FUEL
May 1, 2013
VIRENT DELIVERS TEST VOLUMES OF BIOJET FUEL TO US AIR FORCE LAB
April 23, 2013
NANOBIO’S NOVEL NANOSTAT TECHNOLOGY DEMONSTRATES SIGNIFICANT EFFECTIVENESS AS INTRAMUSCULAR VACCINE ADJUVANT
April 2, 2013
NETSOCKET SECURES $9.2M SERIES B ROUND OF FUNDING
March 28, 2013
CHROMATIN ADDS ROBERT B. SHAPIRO TO BOARD OF DIRECTORS
March 21, 2013
INVIRAGEN: COLORADO BIOTECH’S LATEST MILESTONES EXEMPLIFY BIG-PICTURE PROGRESS TOWARD A DENGUE VACCINE
March 16, 2013
ALFALIGHT SELLS COMMERCIAL COMPONENT PRODUCT LINE TO COMPOUND PHOTONICS; HIGH EFFICIENCY AND WAVELENGTH STABILIZED LASER TECHNOLOGY IS KEY
March 15, 2013
VIRENT: BIOFUEL FIRM QUICKLY MOVING FORWARD
March 13, 2013
CELLERATION REACHES KEY MILESTONE OF 1 MILLION MIST THERAPY TREATMENTS
March 11, 2013
CHROMATIN SIGNS PACT WITH POET TO USE SOUTH DAKOTA-GROWN SORGHUM IN ETHANOL PRODUCTION
March 8, 2013
RESHAPE MEDICAL COMPLETES ENROLLMENT OF PIVOTAL CLINICAL TRIAL FOR WEIGHT LOSS DEVICE
March 1, 2013
INVIRAGEN BEGINS SECOND STAGE OF PHASE II STUDY OF DENGUE VACCINE, DENVAX
March 1, 2013
NON-SURGICAL WEIGHT LOSS DEVICES – AN INTERVIEW WITH RICHARD THOMPSON, CEO, RESHAPE MEDICAL
February 22, 2013
CHROMATIN SIGNS SORGHUM SUPPLY DEAL WITH AEMETIS
February 21, 2013
NEUROVANCE RECEIVES NOTICE OF ALLOWANCE FOR COMPOSITION OF MATTER PATENT AND INITIATES CLINICAL TRIAL OF NEW SR FORMULATION OF EB-1020
February 18, 2013
CHROMATIN AND PACIFIC ETHANOL SIGN MULTI-YEAR AGREEMENT FOR LOCALLY-GROWN SORGHUM IN ETHANOL PRODUCTION
February 4, 2013
CHROMATIN’S DIRECTOR OF FIELD OPERATIONS, LARRY MCDOWELL, BECOMES PRESIDENT OF TEXAS SEED TRADE ASSOCIATION
January 30, 2013
JUVENTAS THERAPEUTICS, INC. HIRES BIOTECHNOLOGY VETERAN PAUL RESNICK AS VICE PRESIDENT OF BUSINESS DEVELOPMENT
January 21, 2013
CHROMATIN TO HOST MODESTO, CALIFORNIA GROWER MEETING TO DISCUSS GRAIN SORGHUM PRODUCTION OPPORTUNITIES FOR ETHANOL
January 20, 2013
TISSUE REGENERATION SYSTEMS: GROWTH FACTOR-UM SPINOFF AIMS TO USE MESH TO CREATE BONE
January 14, 2013
WOUND-HEALING FIRM CELLERATION CLOSING IN ON $7M ROUND OF FUNDING
December 27, 2012
CHROMATIN: SORGHUM U WILL HIGHLIGHT PROFITABILITY, WATER MANAGEMENT
December 15, 2012
CHLOROFILL AND CHROMATIN PARTNER TO HARVEST SORGHUM BIOMASS FOR THE PRODUCTION OF RENEWABLE BUILDING MATERIALS
December 7, 2012
CHROMATIN: GRAIN SORGHUM WELL RECEIVED IN CALIFORNIA TRIAL
November 29, 2012
NANOBIO SEALS $11M SERIES C
November 8, 2012
INVIRAGEN AND THE INTERNATIONAL VACCINE INSTITUTE EXPAND PARTNERSBHIP
October 25, 2012
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
October 18, 2012
NEUROVANCE: CAMBRIDGE BIOTECH SPINOFF RAISES $7M FOR NEW ATTENTION DEFICIT DRUG
October 11, 2012
EUTHYMICS COMPLETES ENROLLMENT IN TRIADE, ITS ADVANCED TRIAL OF AMITIFADINE FOR MAJOR DEPRESSIVE DISORDER
October 9, 2012
NANOBIO PROMOTES DAVID PERALTA TO CHIEF EXECUTIVE OFFICER
October 5, 2012
AERPIO COMES TO THE “RESCUE” WITH HPTP-BETA DRUG FOR DME
September 25, 2012
NOVELOS BRINGING LIGHT TO THE DARKNESS FOR CANCER VICTIMS
September 6, 2012
NEUWAVE MEDICAL RAISES $14M IN VENTURE FUNDING
September 1, 2012
PROCERTUS BIOPHARM TACKLES THE UNPLEASANT SIDE EFFECTS OF CANCER TREATMENT
September 1, 2012
PROCERTUS BIOPHARM TACKLES THE UNPLEASANT SIDE EFFECTS OF CANCER TREATMENT
August 30, 2012
AERPIO THERAPEUTICS COMPLETES $27M SERIES A FINANCING
August 28, 2012
NOVELOS THERAPEUTICS DEVELOPING CLR1502 (GLOW2) CANCER-TARGETED OPTICAL IMAGING AGENT FOR INTRAOPERATIVE TUMOR MARGIN ILLUMINATION
August 27, 2012
JUVENTAS: DRUG BUOYS CLEVELAND COMPANY’S STEM-CELL ASPIRATION
August 20, 2012
JUVENTAS THERAPEUTICS DOSES FIRST PATIENT IN PHASE II STOP-HF TRIAL
August 9, 2012
VMWARE SNACKS ON PATTERN INSIGHT’S LOG TOOL
July 16, 2012
JUVENTAS THERAPEUTICS RAISES $22.2 MILLION SERIES B FINANCING
June 21, 2012
NOVELOS DOSES THREE PATIENTS IN PHASE 1/2 PET IMAGING TRIAL FOR METASTATIC BRAIN CANCER
June 19, 2012
NOVELOS: POSITIVE INITIAL IMAGING RESULTS FROM LIGHT PHASE I/II TRIAL OBSERVED
June 19, 2012
NOVELOS THERAPEUTICS ANNOUNCES POSITIVE INITIAL IMAGING RESULTS IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
May 21, 2012
VIRENT WELCOMES JOHN RICE TO BOARD
May 14, 2012
CELLERATION, INC. ANNOUNCES FIRST PATIENT ENROLLMENT IN IN-BALANCE VLU RANDOMIZED CONTROL TRIAL
May 10, 2012
AERPIO APPOINTS DR. ADRIENNE GRAVES TO BOARD OF DIRECTORS
April 20, 2012
2012 INNOVATION AWARDS: EMERGING INNOVATION WINNER AKEBIA
April 20, 2012
AERPIO ANNOUNCES POSITIVE PHASE 1 DATA ON FIRST-IN-CLASS TIE2 ACTIVATOR, AKB-9778, IN DEVELOPMENT FOR DIABETIC MACULAR EDEMA
April 18, 2012
VIRENT: WANT TO CUT RELIANCE ON FOREIGN OIL? REPLACE THE WHOLE BARREL
April 10, 2012
PATTERN INSIGHT LAUNCHES BETA VERSION OF ITS IT ANALYTICS SOLUTION FOR BIG DATA
April 5, 2012
AKEBIA MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF ONCE-DAILY, ORAL ANEMIA TREATMENT, AKB-6548
March 26, 2012
VIRENT BIOJET FROM VIRDIA CELLULOSIC SUGARS PASSES RIGOROUS TESTS
March 22, 2012
EUTHYMICS BIOSCIENCE, INC. INITIATES CLINICAL TRIAL FOR NEW DRUG TARGETED FOR ADULT ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
March 19, 2012
VENTURE MI II INVESTS $15M IN WISCONSIN EARLY-STAGE FUND
March 12, 2012
INVIRAGEN HAND, FOOT AND MOUTH DISEASE VACCINE GENERATES IMMUNE RESPONSE IN 100% OF STUDY PARTICIPANTS
March 12, 2012
ROCKWELL AUTOMATION ACQUIRES SOFTSWITCHING TECHNOLOGIES, A LEADING PROVIDER OF INDUSTRIAL POWER QUALITY DETECTION AND PROTECTION SYSTEMS
March 7, 2012
CAN VIRENT’S TECHNOLOGY MOVE FROM THE LAB TO THE GAS PUMP?
February 22, 2012
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN LUNG CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
February 15, 2012
VIRENT CEO LEE EDWARDS PROMOTES BENEFITS OF ADVANCED BIOFUELS FOR FARMERS BEFORE SENATE AGRICULTURE COMMITTEE
January 18, 2012
VIRENT BOARD OF DIRECTORS WELCOMES NEW MEMBER
January 18, 2012
NOVELOS THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 1B TRIAL IN SOLID TUMORS WITH (131)I-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC
January 9, 2012
NEW COMPANY, AERPIO THERAPEUTICS, CREATED TO ADVANCE NOVEL TIE-2 ACTIVATORS AND HIF-1A STABILIZERS FOR MULTIPLE DISEASES
January 6, 2012
VIRENT ANNOUNCES ISSUANCE OF FIVE US PATENTS COVERING ITS BIOFORMING TECHNOLOGY
January 4, 2012
CHROMATIN, INC. AWARDED $5.7 MILLION FROM THE DOE TO DEVELOP DROP-IN BIOFUELS
January 4, 2012
CHROMATIN AWARDED $5.7M FROM US DOE TO DEVELOP DROP-IN BIOFUELS
